Efficacy of Postbiotic Supplementation in Improving Antioxidant Status
Effects of Postbiotic Supplementation in Improving Total Antioxidant Status in Healthy Adults
This study will evaluate changes in salivary antioxidant capacity, oxidative stress biomarkers, and self-perceived general well-being during eight weeks of postbiotic supplementation in generally healthy adults.
Thirty-six participants aged 18 years or older will receive MettaBion Liquid twice daily for eight weeks. Assessments will be conducted before supplementation and at Weeks 4 and 8. Saliva samples will be analysed for total antioxidant capacity, malondialdehyde, 3-nitrotyrosine, and 8-hydroxy-2'-deoxyguanosine. General well-being will be assessed using a visual analogue scale.
This prospective, single-arm study will estimate within-participant changes and their variability to inform the design and sample-size planning of a future randomised, placebo-controlled trial.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
This prospective, single-arm, open-label study will evaluate changes in salivary antioxidant capacity, oxidative stress biomarkers, and self-perceived general well-being following eight weeks of postbiotic supplementation in generally healthy adults. The study will recruit 36 participants aged 18 years or older. Assessments will be conducted at baseline, Week 4, and Week 8.
Participants will consume MettaBion Liquid orally for eight weeks, taking one sachet after breakfast and one sachet after dinner each day. Each sachet contains 5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum, providing a total daily intake of 10,000 mg of the preparation. Adherence will be monitored using a participant compliance form.
Unstimulated saliva samples will be collected at each assessment visit to measure total antioxidant capacity (T-AOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG) using Elabscience assay kits. These measurements will assess antioxidant capacity and markers of lipid peroxidation, protein nitration, and oxidative DNA damage, respectively. Participants will also assess their general well-being using a visual analogue scale ranging from 1 to 10, with higher scores indicating better perceived well-being.
The primary outcome will be the change in salivary T-AOC from baseline to Week 8. Secondary outcomes will include the change in salivary T-AOC from baseline to Week 4 and changes in salivary MDA, 3-NT, 8-OHdG, and general well-being scores from baseline to Weeks 4 and 8.
Eligible participants must be generally healthy, willing to follow the study procedures and attend follow-up visits, and able to provide written informed consent before enrolment. Individuals will be excluded if they are currently taking supplements intended to improve antioxidant status, antibiotics, antiviral medicines, or prebiotic or postbiotic supplements; have undergone major surgery within the preceding six months; or are pregnant or breastfeeding.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Chung Keat Tan, PhD
- Telefonnummer: +6017-5063305
- E-post: cktan.jsci@gmail.com
Studiesteder
-
-
Kuala Lumpur
-
Cheras, Kuala Lumpur, Malaysia, 56000
- UCSI University
-
Ta kontakt med:
- Eugenie Sin Sing Tan, PhD
- Telefonnummer: +6016-8924008
- E-post: eugenietan@ucsiuniversity.edu.my
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Generally healthy adults aged 18 years or older.
- Willing to follow the study plan and attend follow-up visits.
- Willing to provide written informed consent before enrolment.
Exclusion Criteria:
- Currently taking supplements intended to improve antioxidant status.
- Currently taking antibiotics or antiviral medicines.
- Currently taking prebiotic or postbiotic supplements.
- Major surgery within the previous six months.
- Pregnant or breastfeeding.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: MettaBion Liquid Supplementation
Participants will consume one sachet of MettaBion Liquid after breakfast and one sachet after dinner daily for eight weeks. Each sachet contains 5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum. |
5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in salivary total antioxidant capacity from baseline to Week 8
Tidsramme: Baseline and Week 8
|
Change in salivary total antioxidant capacity measured using an Elabscience assay kit. |
Baseline and Week 8
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in salivary malondialdehyde
Tidsramme: Baseline and Week 8
|
Change in salivary malondialdehyde, a marker of lipid peroxidation, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Change in salivary 3-nitrotyrosine
Tidsramme: Baseline and Week 8
|
Change in salivary 3-nitrotyrosine, a marker of protein nitration, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Salivary 8-hydroxy-2'-deoxyguanosine (8-OHdG)
Tidsramme: Baseline and Week 8
|
Change in salivary 8-hydroxy-2'-deoxyguanosine, a marker of oxidative DNA damage, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Self-perceived general well-being
Tidsramme: Baseline, Week 4, and Week 8
|
Change in self-perceived general well-being assessed using a visual analogue scale ranging from 1 to 10, with higher scores indicating better general well-being. |
Baseline, Week 4, and Week 8
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
Andre studie-ID-numre
- METTABION - ANTIOXIDANT
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
De-identified individual participant data underlying the published results will be made available to qualified researchers upon reasonable request to the principal investigator. Access will be subject to review of the proposed research purpose, consistency with participant consent and institutional ethics requirements, and a signed data use agreement.
IPD-delingstidsramme
Beginning six months after publication of the study results and continuing for five years.
Tilgangskriterier for IPD-deling
Researchers must submit a methodologically sound proposal outlining the intended use of the data to the principal investigator.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .